Genmab and Incyte announced a Phase 1/2 clinical-trial collaboration on October 24, 2026, targeting first-line metastatic colorectal cancer with a KRAS G12D mutation. The study will combine Genmab’s petosemtamab, Incyte’s INCB161734 and standard chemotherapy.

Under the companies’ announcement, Genmab will run the study. Incyte will co-fund it and provide the investigational KRAS inhibitor, but the partners did not disclose a budget, trial-start date or enrollment target.

Trial pairs two distinct cancer targets

Petosemtamab is a bispecific antibody designed to target EGFR and LGR5. INCB161734 is an oral inhibitor designed for the KRAS G12D mutation. The study will assess both candidates alongside standard chemotherapy.

The scientific rationale is to combine complementary mechanisms in a genetically defined patient group. However, a collaboration announcement does not show safety or efficacy, and early-stage results may not carry into larger trials.

KRAS mutation defines the target population

The companies said KRAS mutations occur in about 40% of colorectal cancers. KRAS G12D accounts for approximately 15% of colorectal cancer cases and is the most common KRAS subtype, according to the release.

Genmab is already testing petosemtamab with chemotherapy in two Phase 3 trials involving RAS/BRAF wild-type metastatic colorectal cancer. Incyte is separately studying INCB161734 in pancreatic cancer and other KRAS G12D solid tumors.

Investor focus shifts to execution and trial design

The collaboration broadens both oncology pipelines without a disclosed upfront payment or milestone structure. Investors should watch the eventual protocol, patient count, trial locations and first-data timing before estimating financial value.

Healthcare demand indicators such as Quest Diagnostics revenue and Danaher life-science sales offer sector context but do not predict clinical success. The companies’ arrangement also differs from data-driven personalized vaccine development, which relies on patient-specific target selection.

Image credit: National Cancer Institute/Unsplash. This article is for informational purposes only and is not investment or medical advice.

Elsy Kanana is a financial and cryptocurrency journalist at FusionMarketNews, covering digital assets, blockchain technology, financial markets, and emerging fintech trends. Her reporting focuses on market movements, regulatory developments, and on-chain analytics, delivering clear, data-driven insights to readers worldwide.